查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703370

基因沉默市場－全球產業規模、佔有率、趨勢、機會和預測（按產品與服務、應用、地區和競爭細分，2020-2030 年）

Gene Silencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service, By Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球基因沉默市場價值為 28.6 億美元，預計到 2030 年將達到 43.6 億美元，預測期內年複合成長率(CAGR) 為 7.48%。

市場概覽
預測期 2026-2030
2024年市場規模 28.6億美元
2030年市場規模 43.6億美元
2025-2030 年複合年成長率 7.48%
成長最快的領域 RNA干擾
最大的市場 北美洲

受分子生物學快速進步、精準醫療日益受到重視以及針對遺傳疾病的有效療法日益成長的需求的推動，該市場正在經歷強勁成長。基因沉默是一種用於抑製或阻止特定基因表現的技術，已成為治療多種疾病（包括癌症、病毒感染和神經系統疾病）的重要工具。

隨著對基因功能的科學理解不斷加深以及研究活動在全球範圍內的擴展，基因沉默將在未來的醫療保健和藥物發現中發揮變革性的作用。

關鍵市場促進因素

醫療保健產業不斷擴張，精準醫療需求不斷成長

主要市場挑戰

交付機制的局限性

主要市場趨勢

RNA療法日益受到關注

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球基因沉默市場的影響

第5章：全球基因沉默市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依產品及服務（RNAi、CRISPR-Cas9、反義寡核苷酸、其他）
    • 按應用（神經病學、腫瘤學、傳染病、代謝疾病、治療製造、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美基因沉默市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲基因沉默市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區基因沉默市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲基因沉默市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲基因沉默市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：全球基因沉默市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Revvity, Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • GenScript Biotech Corporation
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • New England Biolabs, Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 28069

Global Gene Silencing Market was valued at USD 2.86 billion in 2024 and is projected to reach USD 4.36 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.48% during the forecast period.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.86 Billion
Market Size 2030USD 4.36 Billion
CAGR 2025-20307.48%
Fastest Growing SegmentRNAi
Largest MarketNorth America

This market is witnessing strong growth, fueled by rapid advancements in molecular biology, increasing emphasis on precision medicine, and the growing need for effective therapies targeting genetic conditions. Gene silencing-a technique used to suppress or inhibit the expression of specific genes-has become a critical tool in therapeutic development for a broad spectrum of diseases, including cancer, viral infections, and neurological disorders.

As scientific understanding of gene function continues to deepen and research activities expand globally, gene silencing is poised to play a transformative role in the future of healthcare and drug discovery.

Key Market Drivers

Expanding Healthcare Industry and Demand for Precision Medicine

The healthcare sector's transition toward personalized and targeted treatments is a major catalyst for the adoption of gene silencing technologies such as RNA interference (RNAi) and antisense oligonucleotides (ASOs). RNAi, in particular, offers a rapid and effective mechanism for silencing gene expression across various organisms. It operates by breaking down double-stranded RNA into smaller fragments, which then activate enzymes to selectively degrade corresponding messenger RNA (mRNA), ultimately preventing the production of disease-associated proteins.

These technologies enable a high degree of specificity, allowing for the selective suppression of disease-causing genes while sparing healthy tissues-an approach that is especially valuable in areas like oncology, where conventional treatments may be less effective and can cause harmful side effects.

The increasing prevalence of genetic and rare diseases further underscores the need for gene silencing therapies. Disorders such as thalassemia, sickle cell anemia, and glucose-6-phosphate dehydrogenase (G6PD) deficiency-which are often caused by single-gene mutations-represent ideal candidates for gene-targeted approaches. These conditions exhibit substantial molecular and clinical diversity both across and within populations, highlighting the necessity for tailored therapeutic strategies.

Key Market Challenges

Limitations in Delivery Mechanisms

Despite promising developments, the effective delivery of gene silencing agents remains a significant challenge. These molecules must successfully navigate complex biological barriers to reach their intended targets while avoiding degradation by enzymes or clearance by the immune system. Natural defenses-such as nucleases that break down RNA-can compromise the stability and efficacy of these agents before they reach their target cells.

In addition, target-specific delivery remains a critical hurdle. For gene silencing therapies to achieve therapeutic benefit, they must selectively silence disease-related genes without impacting healthy gene expression. However, existing delivery systems often lack the required precision, raising concerns about off-target effects and unintended gene suppression, which can lead to adverse outcomes. This limitation in delivery efficiency and specificity continues to restrict the widespread clinical translation of gene silencing technologies.

Key Market Trends

Rising Interest in RNA-Based Therapeutics

The momentum behind RNA-based therapies-including RNAi and ASOs-continues to grow rapidly. Currently, there are 18 clinically approved RNA-based drugs, including two mRNA vaccines that became globally recognized during the COVID-19 pandemic. These developments have brought RNA-based science into the mainstream, extending its applications from global health emergencies to rare, individualized conditions.

RNAi therapeutics work by degrading specific mRNA molecules, thereby halting the production of disease-causing proteins. ASOs, meanwhile, bind to mRNA sequences to inhibit translation or trigger degradation. These targeted approaches offer precise regulation of gene expression, making them ideal for addressing diseases at the genetic level.

The customizability of RNA-based therapies allows for the treatment of rare and previously untreatable genetic disorders, positioning gene silencing as a cutting-edge solution in modern medicine. Notable approvals such as Patisiran (for hereditary transthyretin-mediated amyloidosis) and Nusinersen (for spinal muscular atrophy) underscore the clinical viability and therapeutic promise of these approaches.

Key Market Players

  • Revvity, Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • GenScript Biotech Corporation
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • New England Biolabs, Inc.

Report Scope

In this report, the Global Gene Silencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Silencing Market, By Product & Service:

  • RNAi
  • CRISPR-Cas9
  • Antisense Oligonucleotides
  • Others

Gene Silencing Market, By Application:

  • Neurology
  • Oncology
  • Infectious Diseases
  • Metabolic Diseases
  • Therapeutics Manufacturing
  • Others

Gene Silencing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Silencing Market.

Available Customizations:

Global Gene Silencing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Gene Silencing Market

5. Global Gene Silencing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product & Service (RNAi, CRISPR-Cas9, Antisense Oligonucleotides, Others)
    • 5.2.2. By Application (Neurology, Oncology, Infectious Diseases, Metabolic Diseases, Therapeutics Manufacturing, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Gene Silencing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product & Service
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gene Silencing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product & Service
        • 6.3.1.2.2. By Application
    • 6.3.2. Mexico Gene Silencing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product & Service
        • 6.3.2.2.2. By Application
    • 6.3.3. Canada Gene Silencing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product & Service
        • 6.3.3.2.2. By Application

7. Europe Gene Silencing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product & Service
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Gene Silencing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product & Service
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Gene Silencing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product & Service
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Gene Silencing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product & Service
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Gene Silencing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product & Service
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Gene Silencing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product & Service
        • 7.3.5.2.2. By Application

8. Asia Pacific Gene Silencing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product & Service
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Gene Silencing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product & Service
        • 8.3.1.2.2. By Application
    • 8.3.2. India Gene Silencing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product & Service
        • 8.3.2.2.2. By Application
    • 8.3.3. South Korea Gene Silencing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product & Service
        • 8.3.3.2.2. By Application
    • 8.3.4. Japan Gene Silencing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product & Service
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Gene Silencing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product & Service
        • 8.3.5.2.2. By Application

9. South America Gene Silencing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product & Service
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Gene Silencing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product & Service
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Gene Silencing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product & Service
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Gene Silencing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product & Service
        • 9.3.3.2.2. By Application

10. Middle East and Africa Gene Silencing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product & Service
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Gene Silencing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product & Service
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Gene Silencing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product & Service
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Gene Silencing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product & Service
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Gene Silencing Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Revvity, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Danaher Corporation
  • 15.3. Agilent Technologies, Inc.
  • 15.4. GenScript Biotech Corporation
  • 15.5. Merck KGaA
  • 15.6. Thermo Fisher Scientific, Inc.
  • 15.7. Illumina, Inc.
  • 15.8. Bio-Rad Laboratories, Inc.
  • 15.9. Bio-Techne Corporation
  • 15.10. New England Biolabs, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer